These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34259144)

  • 41. Radiolabeled Tedizolid Phosphate Liposomes for Topical Application: Design, Characterization, and Evaluation of Cellular Binding Capacity.
    Karpuz M; Atlihan-Gundogdu E; Demir ES; Senyigit Z
    AAPS PharmSciTech; 2021 Feb; 22(2):62. PubMed ID: 33528714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol.
    Huang Y; Zhou D; Hang T; Wu Z; Liu J; Xu Q; Xie X; Zuo J; Wang Z; Zhou Y
    Anticancer Drugs; 2012 Jun; 23(5):515-24. PubMed ID: 22343423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.
    Johnston MJ; Semple SC; Klimuk SK; Edwards K; Eisenhardt ML; Leng EC; Karlsson G; Yanko D; Cullis PR
    Biochim Biophys Acta; 2006 Jan; 1758(1):55-64. PubMed ID: 16487476
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Recent Overview on Dermatological Applications of Liposomes.
    Kushwaha P; Saxena S; Shukla B
    Recent Pat Nanotechnol; 2021; 15(4):310-321. PubMed ID: 33087038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development, characterization and in vivo evaluation of benzocaine-loaded liposomes.
    Mura P; Maestrelli F; González-Rodríguez ML; Michelacci I; Ghelardini C; Rabasco AM
    Eur J Pharm Biopharm; 2007 Aug; 67(1):86-95. PubMed ID: 17350813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of lichen secondary metabolites on Aspergillus fungi.
    Furmanek Ł; Czarnota P; Seaward MRD
    Arch Microbiol; 2021 Dec; 204(1):100. PubMed ID: 34964912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lichen palatability depends on investments in herbivore defence.
    Gauslaa Y
    Oecologia; 2005 Mar; 143(1):94-105. PubMed ID: 15619096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential application of liposomal nanodevices for non-cancer diseases: an update on design, characterization and biopharmaceutical evaluation.
    Bayat F; Hosseinpour-Moghadam R; Mehryab F; Fatahi Y; Shakeri N; Dinarvand R; Ten Hagen TLM; Haeri A
    Adv Colloid Interface Sci; 2020 Mar; 277():102121. PubMed ID: 32092487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lichen-derived compounds show potential for central nervous system therapeutics.
    Reddy RG; Veeraval L; Maitra S; Chollet-Krugler M; Tomasi S; Dévéhat FL; Boustie J; Chakravarty S
    Phytomedicine; 2016 Nov; 23(12):1527-1534. PubMed ID: 27765373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biological activity of selected lichens and lichen-based Ag nanoparticles prepared by a green solid-state mechanochemical approach.
    Goga M; Baláž M; Daneu N; Elečko J; Tkáčiková Ľ; Marcinčinová M; Bačkor M
    Mater Sci Eng C Mater Biol Appl; 2021 Feb; 119():111640. PubMed ID: 33321678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Release rate is a key variable affecting the therapeutic effectiveness of liposomal fasudil for the treatment of cerebral ischemia/reperfusion injury.
    Yanagida Y; Namba M; Fukuta T; Yamamoto H; Yanagida M; Honda M; Oku N; Asai T
    Biochem Biophys Res Commun; 2020 Oct; 531(4):622-627. PubMed ID: 32819716
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biological activities of Pseudevernia furfuracea (L.) Zopf extracts and isolation of the active compounds.
    Güvenç A; Küpeli Akkol E; Süntar I; Keleş H; Yıldız S; Calış I
    J Ethnopharmacol; 2012 Dec; 144(3):726-34. PubMed ID: 23107822
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Diversity of Secondary Metabolites from Some Medicinal Plants and Cultivated Lichen Mycobionts].
    Tanahashi T
    Yakugaku Zasshi; 2017; 137(12):1443-1482. PubMed ID: 29199255
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of doxorubicin liposomal formulations for size-based distribution of drug and excipients using asymmetric-flow field-flow fractionation (AF4) and liquid chromatography-mass spectrometry (LC-MS).
    Ansar SM; Mudalige T
    Int J Pharm; 2020 Jan; 574():118906. PubMed ID: 31805309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical Evaluation of Ropivacaine in 2 Liposomal Modified Systems.
    Rennó CC; Papini JZB; Cereda CMS; Martinez E; Montalli VA; de Paula E; Pedrazzoli Júnior J; Calafatti SA; Tofoli GR
    Anesth Analg; 2019 Aug; 129(2):387-396. PubMed ID: 30303863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy.
    Gardikis K; Hatziantoniou S; Bucos M; Fessas D; Signorelli M; Felekis T; Zervou M; Screttas CG; Steele BR; Ionov M; Micha-Screttas M; Klajnert B; Bryszewska M; Demetzos C
    J Pharm Sci; 2010 Aug; 99(8):3561-71. PubMed ID: 20564386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Manufacturing drug co-loaded liposomal formulations targeting breast cancer: Influence of preparative method on liposomes characteristics and in vitro toxicity.
    Gkionis L; Campbell RA; Aojula H; Harris LK; Tirella A
    Int J Pharm; 2020 Nov; 590():119926. PubMed ID: 33010397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparation of liposomal formulations of ALA Undecanoyl ester for its use in photodynamic therapy.
    Di Venosa G; Hermida L; Fukuda H; Defain MV; Rodriguez L; Mamone L; MacRobert A; Casas A; Batlle A
    J Photochem Photobiol B; 2009 Aug; 96(2):152-8. PubMed ID: 19560367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dissociation and metal-binding characteristics of yellow lichen substances suggest a relationship with site preferences of lichens.
    Hauck M; Jürgens SR; Willenbruch K; Huneck S; Leuschner C
    Ann Bot; 2009 Jan; 103(1):13-22. PubMed ID: 18977765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.